RxDoctor Payments Data

Jerome Lisk, MD

Neurology · Denton, TXNPI 1821036500

Payments from drug & device makers

$214,683in general payments, 2019–2025

Across 551 payments — averaging $389.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$136K
  • Lundbeck LLC$15K
  • Adamas Pharmaceuticals, Inc.$13K
  • H. Lundbeck A S$9K
  • Merz Pharmaceuticals, LLC$9K
  • Merz North America, Inc.$7K
  • plus $26K from 37 others
$10,000in research payments, 2019–2025

Across 3 payments — averaging $3333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$10K

What the payments were for

  • Consulting fees$14,5477%
  • Speaking & faculty fees$154,35175%
  • Travel & lodging$26,11313%
  • Food & beverage$10,8155%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,683 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$262,916
Medicare patients
389
Services billed
2,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Droxidopa162$926,135
AustedoDeutetrabenazine54$640,561
RytaryCarbidopa/Levodopa246$541,513
Austedo XrDeutetrabenazine35$462,299
NuplazidPimavanserin Tartrate81$456,358
GocovriAmantadine Hcl105$279,355
XadagoSafinamide Mesylate62$105,109
Rivastigmine260$49,170
Rasagiline Mesylate235$33,362
Memantine Hcl ErMemantine Hcl428$31,311
MyrbetriqMirabegron26$22,824
BotoxOnabotulinumtoxina14$17,862
LinzessLinaclotide13$14,491
Carbidopa-LevodopaCarbidopa/Levodopa327$12,119
CrexontCarbidopa/Levodopa16$11,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$135,826$1,102,86089 claims
Amneal Pharmaceuticals LLCRytary, Crexont$4,523$552,913262 claims
Acadia Pharmaceuticals IncNuplazid$342$456,35881 claims
MDD US Operations, LLCGocovri$4,802$279,355105 claims
AbbVieBotox, Linzess$524$32,35327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →